You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

 

Online download statistics by month:

Online download statistics by month: December 2019 to May 2026

AbstractFullPdf
Dec 2019330
Jan 202024242
Feb 202032327
Mar 202058586
Apr 202064643
May 202067678
Jun 202038386
Jul 2020994
Aug 2020212112
Sep 2020323241
Oct 2020343457
Nov 2020232324
Dec 2020292916
Jan 2021232312
Feb 2021191912
Mar 2021222210
Apr 2021212319
May 2021181814
Jun 2021323214
Jul 2021323221
Aug 2021181817
Sep 2021515131
Oct 2021424243
Nov 2021222219
Dec 202151516
Jan 2022323510
Feb 2022454514
Mar 2022222415
Apr 2022232732
May 2022242422
Jun 2022131310
Jul 2022303214
Aug 202220206
Sep 2022202223
Oct 2022181914
Nov 2022182016
Dec 2022444417
Jan 2023252518
Feb 2023242411
Mar 2023676820
Apr 2023181912
May 2023424212
Jun 202321219
Jul 2023242415
Aug 2023313314
Sep 2023292917
Oct 2023303018
Nov 2023353519
Dec 2023242420
Jan 2024373982
Feb 2024424315
Mar 2024404020
Apr 2024303115
May 202428285
Jun 2024343416
Jul 2024464614
Aug 2024202011
Sep 2024282927
Oct 2024323419
Nov 2024404215
Dec 2024697019
Jan 2025494935
Feb 202512412720
Mar 2025505012
Apr 2025606020
May 2025343417
Jun 2025323212
Feb 2026110
May 2026220
Total226222971156